World News: 11:05 GMT Thursday 14th June 2018. [Nightstar Therapeutics via Thomson Reuters ONE via SPi World News]
First gene therapy RMAT designation for an inherited retinal disease STAR Phase 3 registrational trial ongoing and FDA interactions planned RMAT designation enables closer and more frequent multidisciplinary interaction with FDA with all of t he bene...
Thomson Reuters: 11:05 GMT Thursday 14th June 2018
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.